Literature DB >> 8300251

Short course intermittent chemotherapy in childhood tuberculosis.

A Göçmen1, U Ozçelic, N Kiper, M Toppare, S Kaya, R Cengizlier, F Cetinkaya.   

Abstract

A total of 130 children diagnosed as having pulmonary and extrapulmonary tuberculosis who received short course intermittent chemotherapy between 1978-1992 were evaluated retrospectively. One hundred and ten children with tuberculosis were treated with isoniazid (10-15 mg/kg, maximum 400 mg), rifampin (10-15 mg/kg, maximum 600 mg), and streptomycin (30 mg/kg, maximum 1 g) daily, for 15 days. Treatment was completed with similar doses of isoniazid and rifampin twice a week for a period of 9 months. Since 1986, 20 children with tuberculosis were being treated with the same regimen but without streptomycin. The majority of patients in these cases had pulmonary tuberculosis (75%), followed by lymph nodes (9%), pleural (7%), bone and joint (5%), miliary (3%), and abdominal tuberculosis (1%). The clinicoradiologic response to treatment was observed to be excellent. Only one case of relapse was detected, which was the case of a patient with lymph node tuberculosis that occurred 18 months after the completion of treatment. No serious adverse drug reaction was observed in any of the cases mentioned. In conclusion, short-course low-dose intermittent chemotherapy is an effective and economical treatment with minimal side effects for pulmonary and extrapulmonary tuberculosis in childhood.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8300251     DOI: 10.1007/BF01712456

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  20 in total

1.  A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis.

Authors:  L Kumar; R Dhand; P D Singhi; K L Rao; S Katariya
Journal:  Pediatr Infect Dis J       Date:  1990-11       Impact factor: 2.129

2.  Short course chemotherapy for childhood tuberculosis.

Authors:  J Biddulph
Journal:  Pediatr Infect Dis J       Date:  1990-11       Impact factor: 2.129

3.  American Academy of Pediatrics Committee on Infectious Diseases: Chemotherapy for tuberculosis in infants and children.

Authors: 
Journal:  Pediatrics       Date:  1992-01       Impact factor: 7.124

4.  Short course chemotherapy in childhood tuberculosis.

Authors:  J Biddulph; V Kokoha; S Sharma
Journal:  J Trop Pediatr       Date:  1988-02       Impact factor: 1.165

Review 5.  Philip Ellman lecture. The modern management and therapy of pulmonary tuberculosis.

Authors:  W Fox
Journal:  Proc R Soc Med       Date:  1977-01

6.  The action of antituberculosis drugs in short-course chemotherapy.

Authors:  D A Mitchison
Journal:  Tubercle       Date:  1985-09

7.  American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1986-08

8.  Short-course chemotherapy of tuberculosis with largely twice-weekly isoniazid-rifampin.

Authors:  A K Dutt; L Jones; W W Stead
Journal:  Chest       Date:  1979-04       Impact factor: 9.410

9.  Short-course chemotherapy for tuberculosis in children.

Authors:  R S Abernathy; A K Dutt; W W Stead; D J Moers
Journal:  Pediatrics       Date:  1983-12       Impact factor: 7.124

10.  ACONCURRENT COMPARISON OF INTERMITTENT (TWICE-WEEKLY) ISONIAZID PLUS STREPTOMYCIN AND DAILY ISONIAZID PLUS PAS IN THE DOMICILIARY TREATMENT OF PULMONARY TUBERCULOSIS; TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS.

Authors:  A LOTTE; F HATTON; S PERDRIZET; A ROUILLON
Journal:  Bull World Health Organ       Date:  1964       Impact factor: 9.408

View more
  1 in total

1.  Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

Authors:  S M Graham; D J Bell; S Nyirongo; R Hartkoorn; S A Ward; E M Molyneux
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.